Guidelines for treatment of renal injury during cancer chemotherapy 2016

Horie, Shigeo; Oya, Mototsugu; Nangaku, Masaomi; Yasuda, Yoshinari; Komatsu, Yasuhiro; Yanagita, Motoko; Kitagawa, Yuko; Kuwano, Hiroyuki; Nishiyama, Hiroyuki; Ishioka, Chikashi; Takaishi, Hiromasa; Shimodaira, Hideki; Mogi, Akira; Ando, Yumiko; Matsumoto, Koji; Kadowaki, Daisuke; Muto, Satoru

doi:10.1007/s10157-017-1448-z

Cited by 63 publications

(50 citation statements)

References 160 publications

(125 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The chemotherapeutic agents have many complications such as hematological and immunological derangements as well as renal dysfunctions [1]. Carboplatin is one of platinumcontaining chemotherapeutic drugs and alkylating agents.…”

Section: Introductionmentioning

confidence: 99%

The Role of Erythropoietin , Vitamin C and L-NAME in Carboplatin- Induced Hematological and Renal Dysfunctions

Elgendy

Elsaed

Badawy

2019

BESPS

View full text Add to dashboard Cite

Carboplatin is a neoplastic agent causing hematotoxicity, erythropoietin (EPO) resistance, increase oxidative stress and pro-inflammatory cytokines. Our study investigated the role of erythropoietin, vitamin C and L-NAME in carboplatin-induced hematological and renal dysfunctions. Seventy rats divided into seven groups; control, Carboplatin (100 mg/kg.), Carboplatin (250 mg/kg), Carboplatin (100 mg/kg.) pretreated by EPO , Carboplatin (250 mg/kg) pretreated by EPO, Carboplatin (250 mg/kg) pretreated by EPO & Vitamin C and Carboplatin (250 mg/kg) pretreated by EPO & L-NAME. Hematological, plasma inflammatory cytokines, renal functions , oxidant, antioxidant parameters , serum EPO and vitamin C were measured with histopathology of renal tissue. Carboplatin decreased RBC count, hemoglobin concentration, packed cells volume, platelets count , superoxide dismutase , catalase and glutathione peroxidase, serum erythropoietin and vitamin C while WBCs count, interleukin 1, interleukin 6, tumor necrosis factor alpha, high-sensitivity C-reactive protein, serum blood urea nitrogen, serum creatinine, malondialdehyde and nitric oxide were increased. Vitamin C and L-NAME improved hematological derangement, EPO resistance, antioxidant parameters and histopathological findings while worsen plasma inflammatory markers, renal functions parameters and oxidative parameters. There was insignificant change in blood indices in all groups. We concluded that carboplatin had a hematological toxicity and oxidant stress effect in addition to increase proinflammatory cytokines and consequent renal insult. The development of EPO resistance was carboplatindose dependent. Vitamin C and L-NAME alleviate the hematological toxicity, oxidative stress, EPO resistance and decrease proinflammatory cytokines and in turn recovery of renal structure and functions.

show abstract

Section: Introductionmentioning

confidence: 99%

The Role of Erythropoietin , Vitamin C and L-NAME in Carboplatin- Induced Hematological and Renal Dysfunctions

Elgendy

Elsaed

Badawy

2019

BESPS

View full text Add to dashboard Cite

show abstract

“…We retrospectively evaluated the clinical data for patient characteristics (age, sex, histology, epidermal growth factor receptor [ EGFR ] gene mutation status, previous treatment, evidence of distant metastasis, Eastern Cooperative Oncology Group PS, and smoking history), dosage and schedule of docetaxel chemotherapy, clinical course, and concurrent use of other drugs such as nonsteroidal anti‐inflammatory drugs. The eGFR was calculated using the Japanese Society of Nephrology formula . We examined the data on hematologic and nonhematologic toxicities during the entire course of docetaxel chemotherapy.…”

Section: Methodsmentioning

confidence: 99%

“…The eGFR was calculated using the Japanese Society of Nephrology formula. 16 We examined the data on hematologic and nonhematologic toxicities during the entire course of docetaxel chemotherapy. Severe toxicity was defined as hematological toxicity of grade ≥4 or nonhematological toxicity of grade ≥3 according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0).…”

Section: Patients and Clinical Informationmentioning

confidence: 99%

Retrospective cohort study on the safety and efficacy of docetaxel in Japanese non‐small cell lung cancer patients with nondialysis chronic kidney disease stage 3b or higher

et al. 2019

View full text Add to dashboard Cite

BackgroundIt has been reported that 20% of lung cancer patients have renal impairment caused by chronic kidney disease (CKD). Since docetaxel is predominantly excreted by the hepatobiliary system, it is administered to non‐small cell lung cancer (NSCLC) patients with renal impairment. However, few clinical data are available on the toxicity and efficacy of docetaxel for patients with nondialysis renal impairment. Furthermore, some cases of tubular nephrotoxicity caused by docetaxel in NSCLC patients have been reported. Therefore, a retrospective cohort study was conducted to assess the influence of nondialysis CKD on the toxicity and efficacy of docetaxel in NSCLC patients.MethodsNSCLC patients who received docetaxel were assessed for renal function, occurrence of adverse events and treatment efficacy.ResultsA total of 34 NSCLC patients who received docetaxel were studied. Eight (23.5%) patients had nondialysis CKD stage 3b or higher, with an estimated glomerular filtration rate (eGFR) <45 mL/min/1.73 m2. Although the differences were not statistically significant, the starting dose of docetaxel (mg/m2) was lower (60 mg/m2; 37.5% vs. 69.2%) in patients with an eGFR <45 than that in patients with an eGFR ≥45. No significant association was observed between pretreatment eGFR and hematological and nonhematological toxicities. No significant difference was observed in the disease control rate (62.5% vs. 65.4%, P = 1.000) or in the median overall survival (10.7 vs. 11.7, P = 0.735) between patients with an eGFR <45 and those with an eGFR ≥45.ConclusionDocetaxel is a reasonable option for NSCLC patients with nondialysis CKD stage 3b or higher. Dose reduction of docetaxel is also a possibility for NSCLC patients with CKD stage 3b or higher.

show abstract

“…Yuichi Ando (Japan) discussed the guidelines for treatment of renal injury during chemotherapy. 9 Onconephrology has emerged as a new field concerned with the management of nephrotoxicity during anticancer therapy. He mentioned the importance of risk assessment to prevent cisplatin-induced AKI.…”

Section: Overview Of the 2018 Isn Frontiers Meetingmentioning

confidence: 99%

Summary of the 2018 ISN Frontiers Meeting: Kidney Disease and Cardiovascular Disease

Kume

Nagasu

Nangaku

et al. 2018

Kidney International Reports

Self Cite

View full text Add to dashboard Cite

International Society of Nephrology (ISN) Frontiers meetings build on the success of the ISN Nexus and Forefronts series by bringing together basic scientists, clinicians, and practitioners in a unique setting. This new event was organized to make more innovative science available to a global audience by removing regional barriers in accessing the latest knowledge. The first ISN Frontiers meeting was organized in partnership between the Japanese Society of Nephrology and the Japanese Society for Dialysis Therapy, which was held in Tokyo in February 2018. The meeting focused on the topic “Kidney Disease & Cardiovascular Disease,” which covered a broad range of scientific and clinical fields, including nephrology, cardiovascular diseases, dialysis, transplantation, chronic kidney disease (CKD)–mineral bone disease (MBD), diabetes, pediatric nephrology, nutrition, pharmacology, and nursing. A total of 1584 active physicians and scientists from 64 countries attended the meeting, and a number of leading physician scientists from different and related disciplines of clinical and basic research described and reviewed recent discoveries. This report summarizes the main highlights of the meeting lectures.

show abstract

Guidelines for treatment of renal injury during cancer chemotherapy 2016

Cited by 63 publications

References 160 publications

The Role of Erythropoietin , Vitamin C and L-NAME in Carboplatin- Induced Hematological and Renal Dysfunctions

The Role of Erythropoietin , Vitamin C and L-NAME in Carboplatin- Induced Hematological and Renal Dysfunctions

Retrospective cohort study on the safety and efficacy of docetaxel in Japanese non‐small cell lung cancer patients with nondialysis chronic kidney disease stage 3b or higher

Summary of the 2018 ISN Frontiers Meeting: Kidney Disease and Cardiovascular Disease

Contact Info

Product

Resources

About